BioGnost’s internationalization project has been approved to enhance the company’s global competitiveness.

We are pleased to announce that funding has been approved for our internationalization project under the “Support for SMEs in Internationalization” call, within the framework of the “Competitiveness and Cohesion 2021–2027” Programme. This grant represents an important step in further development and positioning of BioGnost on the global market.

The project titled “BioGnost – Innovative Diagnostics for the International Market” is designed to elevate our global competitiveness by showcasing our latest advancements at two premier international medical diagnostics trade fairs: Medica Düsseldorf and WHX Labs Dubai (formerly known as Medlab Middle East Dubai). These flagship industry events gather leading experts and decision-makers in diagnostics and laboratory medicine, offering us an exceptional platform to highlight our portfolio of innovative, high-quality and eco-friendly reagents to a worldwide audience.

Through this project, we aim to significantly enhance brand visibility and expand our global reach by establishing new strategic partnerships across international markets. With this support, BioGnost is poised to strengthen its reputation as a trusted provider of diagnostic solutions and unlock exciting new opportunities for growth on the global stage.

The project was co-financed by the European Union from the Competitiveness and Cohesion Programme 2021–2027. The content of this publication is the sole responsibility of BioGnost Ltd. and does not necessarily reflect the views of the European Union or the competent authorities.